CLE
Clinical trials for CLE explained in plain language.
Never miss a new study
Get alerted when new CLE trials appear
Sign up with your email to follow new studies for CLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody drug takes aim at autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…
Matched conditions: CLE
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill VENT-03 aims to calm lupus skin flares
Disease control Recruiting nowThis study tests an experimental tablet called VENT-03 for people with active cutaneous lupus erythematosus (CLE), a condition causing painful skin rashes. Twenty-four adults will take either VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. Researche…
Matched conditions: CLE
Phase 2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC